Provided by Tiger Trade Technology Pte. Ltd.

Roivant Sciences Ltd.

27.67
+1.857.16%
Pre-market: 27.860.1900+0.69%08:30 EST
Volume:17.12M
Turnover:458.79M
Market Cap:19.80B
PE:-23.58
High:27.72
Open:26.35
Low:25.72
Close:25.82
52wk High:27.72
52wk Low:8.73
Shares:715.70M
Float Shares:467.00M
Volume Ratio:1.79
T/O Rate:3.67%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.1734
EPS(LYR):-0.2371
ROE:-19.14%
ROA:-14.47%
PB:4.64
PE(LYR):-116.71

Loading ...

Roivant Sciences price target raised to $35 from $26 at Citi

TIPRANKS
·
1 hour ago

Roivant Sciences Is Maintained at Buy by Guggenheim

Dow Jones
·
Yesterday

Roivant Sciences price target raised to $26 from $22 at BofA

TIPRANKS
·
Yesterday

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Immunovant (IMVT) and Roivant Sciences (ROIV)

TIPRANKS
·
Yesterday

Roivant Sciences (ROIV) Q3 Loss Of US$265.9 Million Tests Bullish Profitability Narrative

Simply Wall St.
·
Feb 08

Roivant Sciences (ROIV) Is Up 19.4% After Advancing Phase 2 Pipeline Despite Wider Quarterly Loss

Simply Wall St.
·
Feb 07

Analysts Are Bullish on These Healthcare Stocks: Knight Therapeutics (KHTRF), Roivant Sciences (ROIV)

TIPRANKS
·
Feb 07

BUZZ-U.S. STOCKS ON THE MOVE-SpyGlass, Agomab, Piper Sandler, Molina

Reuters
·
Feb 07

Roivant Sciences Up Over 17%, on Track for Record High Close -- Data Talk

Dow Jones
·
Feb 07

BUZZ-U.S. STOCKS ON THE MOVE-Microchip, Under Armour, Avery Dennison

Reuters
·
Feb 06

Roivant Sciences rises 16.9%

TIPRANKS
·
Feb 06

Stock Track | Roivant Sciences Soars 19.68% Intraday on Positive Phase 2 Results for Skin Disease Drug

Stock Track
·
Feb 06

Roivant Shares Rise on Positive Skin Disease Treatment Results

Dow Jones
·
Feb 06

Wall Street Set to Open Modestly Higher Friday as Tech Stocks Stabilize Following Week-Long Rout

MT Newswires Live
·
Feb 06

BRIEF-Priovant Announces Positive Phase 2 Results For Brepocitinib In Cutaneous Sarcoidosis (Cs)

Reuters
·
Feb 06

Priovant's Brepocitinib Shows Skin Disease Improvement in Phase 2 Study; Pulmovant Completes Lung Disease Trial Enrollment

MT Newswires Live
·
Feb 06

Shares of Roivant up 15.8% Premarket After Experimental Drug Shows Benefit in Rare Skin Disease, Q3 Results

THOMSON REUTERS
·
Feb 06

Roivant Sciences posts nine-month revenue of USD 5.74 million, down 73 percent

Reuters
·
Feb 06

S&P 500 Futures Climb In Premarket Trading; Doximity, Stellantis Lag

Dow Jones
·
Feb 06

BUZZ-Roivant shares rise as experimental drug shows benefit in rare skin disease

Reuters
·
Feb 06